These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6949385)

  • 1. Alloimmunization and adoptive immunotherapy of leukemia.
    Truitt RL; Shih CY; Rimm AA; Tempelis LD; Bortin MM
    Transplant Proc; 1981 Dec; 13(4):1910-4. PubMed ID: 6949385
    [No Abstract]   [Full Text] [Related]  

  • 2. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL; Bortin MM; Rimm AA
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy.
    Bortin MM; Rimm AA; Rodey GE; Giller R; Saltzstein EC
    Cancer Res; 1974 Aug; 34(8):1851-6. PubMed ID: 4152270
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Albala MM
    Cancer Res; 1975 Mar; 35(3):637-9. PubMed ID: 234789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Flinton LJ; Simon JD; Kelley RJ; Albala MM
    Cancer Res; 1977 Oct; 37(10):3494-6. PubMed ID: 20223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H-2 restriction of adoptive immunotherapy of advanced tumors.
    Greenberg PD; Cheever MA; Fefer A
    J Immunol; 1981 Jun; 126(6):2100-3. PubMed ID: 6453154
    [No Abstract]   [Full Text] [Related]  

  • 8. Alloimmunization for induction of graft-versus-leukemia reactivity in H-2-compatible donors: critical role for incompatibility of donor and alloimmunizing strains at non-H-2 loci.
    Bortin MM; Truitt RL; Shih CY; Tempelis LD; LeFever AV; Rimm AA
    Transplant Proc; 1983 Dec; 15(4):2114-7. PubMed ID: 6673211
    [No Abstract]   [Full Text] [Related]  

  • 9. Graft versus leukemia. VIII. Selective reduction in antihost reactivity without loss of antileukemic reactivity by treatment of donor mice with lipopolysaccharide.
    Truitt RL; Rose WC; Rimm AA; Bortin MM
    Exp Hematol; 1978 May; 6(5):488-98. PubMed ID: 26584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia.
    Bortin MM; Rimm AA; Saltzstein EC
    Science; 1973 Feb; 179(4075):811-3. PubMed ID: 4405359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft versus leukemia. VI. Adoptive immunotherapy in combination with chemoradiotherapy for spontaneous leukemia-lymphoma in AKR mice.
    Bortin MM; Rose WC; Truitt RL; Rimm AA; Saltzstein EC; Rodey GE
    J Natl Cancer Inst; 1975 Nov; 55(5):1227-9. PubMed ID: 1546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of normal allogeneic responder cells in mouse mixed leukocyte culture by long-passage AKR leukemic lymphoblasts.
    Rodey GE; Sprader JC; Bortin MM
    Cancer Res; 1974 Jun; 34(6):1289-94. PubMed ID: 4275007
    [No Abstract]   [Full Text] [Related]  

  • 14. Specific graft-versus-host nonreactivity of lymphoid cells from irradiation chimeras.
    Norin AJ; Emeson EE; Veith FJ
    Transplant Proc; 1981 Mar; 13(1 Pt 2):1241-4. PubMed ID: 7268889
    [No Abstract]   [Full Text] [Related]  

  • 15. Modulation of the recognition and lysis of EL4 tumor target cells by cytotoxic T lymphocytes.
    Gilmer PJ; Figard SD; Flores RV; DiRoma PJ
    Cell Immunol; 1982 Nov; 73(2):337-48. PubMed ID: 6984363
    [No Abstract]   [Full Text] [Related]  

  • 16. Adoptive immunochemotherapy of a transplantable AKR leukemia (K36).
    Putman DL; Kind PD; Goldin A; Kende M
    Int J Cancer; 1978 Feb; 21(2):230-3. PubMed ID: 24004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Increase of the GvH reaction after alloimmunization. Influence of the serologically defined determinants of the H-2 system].
    Brock J; Siegl E; Schulze HA
    Allerg Immunol (Leipz); 1982; 28(2):91-6. PubMed ID: 6182783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy and combined chemo-immunotherapy in transplantable leukaemia of AKR mice (TAL); occurrence of natural killers.
    Schneiberg K; Rytwiński K; Tabeńska J
    Haematologia (Budap); 1981; 14(2):137-46. PubMed ID: 7274781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.